The thing that can influence bDMARD choice in PsA are the extra-MSK manifestations “A little bit of a paradigm shift here” - Laure Gossec 2023 @eular_org recommendations #EULAR2023 @RheumNow https://t.co/gr9IOg1bbj

Which bDMARD first in PsA? 2023 @eular_org recommendation: no preferred order. All are equal in its eyes #EULAR2023 @RheumNow https://t.co/6HNNamAj1J

PsA recommendations update at #EULAR2023 New overarching principles - should take account of safety @rheumnow https://t.co/rrZ0ViFRPs

Here are the PsA drugs that have come to market in recent years (and what a few years it’s been) #EULAR2023 @RheumNow https://t.co/asFsHAD21y

PsA update at #EULAR2023 new mechanisms of actions since the 2019 guidelines @RheumNow https://t.co/zaieEHN6sW

ILD in RA and PsA @AurelieRheumo discusses inconsistent data inconsistent data have proposed on the effect of bio/tsDMARDs on the risk of ILD. ILD is a severe extra articular manifestation of RA, with limited treatment strategies and poor prognosis. https://t.co/U1RjvgTCL8 https://t.co/qmxXBTK05N

• https://bit.ly/3oIxxnR

Metabolic Burden in the Early Stages of PsA Dr. Aurelie Najm ( @AurelieRheumo )discusses abstract OP0066 presented at EULAR 2023 in Milan, Italy. https://t.co/Z39ibke3JD https://t.co/YvWbNz9tFH

• https://bit.ly/3JcZawv

Tune it at 1pm EST for RheumNow's daily #EULAR23 recaps. You can find us live on Twitter, YouTube and LinkedIn. https://t.co/t531csjXo8